Does Beta-Thalassemia Gene Therapy Cause Infertility?
At a Glance
Yes, there is a very high risk of infertility following stem cell transplants and gene therapy for beta-thalassemia. The preparatory chemotherapy, called myeloablative conditioning, permanently damages reproductive organs. Patients should consult a specialist for fertility preservation before treatment.
In this answer
4 sections
Yes, there is a very high risk that undergoing a stem cell transplant or gene therapy for beta-thalassemia will cause infertility. While these treatments offer the possibility of a lifelong cure, the process requires powerful chemotherapy drugs that often permanently damage reproductive organs [1][2]. Because of this significant risk, it is essential to discuss fertility preservation options with your or your child’s medical team before starting any treatment [3][4].
Why Curative Treatments Impact Fertility
To understand why these treatments cause infertility, it helps to understand how they work. Whether a patient receives a traditional stem cell transplant or a newer gene therapy (such as betibeglogene autotemcel, also known as Zynteglo), the body must first undergo a process called myeloablative conditioning [5][6].
During myeloablative conditioning, high doses of chemotherapy—most commonly a drug called busulfan—are given to clear out the existing, flawed bone marrow [6][7]. This makes room for the new, healthy stem cells to take hold and grow [5]. Unfortunately, chemotherapy drugs like busulfan are highly gonadotoxic, meaning they are exceptionally harsh on the reproductive organs (the gonads) [1][8].
- In females: The chemotherapy can destroy the resting eggs in the ovaries, often leading to premature ovarian insufficiency (where the ovaries stop functioning years or decades earlier than normal) [9][7].
- In males: The chemotherapy disrupts the environment inside the testicles and can permanently damage the stem cells responsible for producing sperm [8][10].
Some treatment centers are researching alternative conditioning drugs (such as treosulfan) that may be less damaging to fertility, but the risk of long-term reproductive complications remains high [11][12].
It is also important to know that preserving fertility (saving eggs, sperm, or tissue) is not the same as preserving normal hormone function. Because the conditioning chemotherapy damages the reproductive organs, many patients will still require lifelong hormone replacement therapy (HRT) to support normal puberty, sexual function, and bone health [7][13].
The Added Challenge of Iron Overload
Even before a transplant or gene therapy begins, people with beta-thalassemia major may already have a higher risk of fertility challenges [14]. Years of regular blood transfusions can lead to iron overload in the body [15]. If excess iron builds up in the pituitary gland or reproductive organs, it can cause hypogonadotropic hypogonadism—a condition where the body does not produce enough of the hormones needed for puberty or reproduction [16][17]. This pre-existing condition makes it even more important to have a specialized reproductive endocrinologist involved in your or your child’s care [13].
Protecting Future Fertility: Options and Timelines
Because the risk of infertility from conditioning chemotherapy is well-known, medical guidelines strongly recommend fertility preservation before treatment begins [18][4]. The available options depend on the patient’s age and stage of puberty:
- Post-pubertal patients: The most established methods are freezing mature eggs (oocyte cryopreservation) for females and freezing sperm (sperm banking) for males. Egg freezing typically requires a few weeks of daily hormone injections.
- Pre-pubertal children: Because young children do not yet produce mature eggs or sperm, they require different approaches [19]. Gonadal tissue cryopreservation involves surgically removing and freezing small pieces of ovarian tissue for girls, or testicular tissue for boys [20][21]. While ovarian tissue freezing has successfully led to pregnancies, testicular tissue freezing is still considered experimental [22][19]. Both procedures require anesthesia and recovery time.
Timing is critical. These preservation procedures take time and must be carefully planned with the hematology team so they do not unnecessarily delay the life-saving transplant or gene therapy [23].
Next Steps and Navigating the Challenges
The grief and difficult decisions surrounding infertility are some of the hardest parts of pursuing a cure for beta-thalassemia. It is completely normal to feel overwhelmed by having to make choices about future fertility when focused on a life-threatening disease.
- Ask for an immediate referral: Request an appointment with an oncofertility specialist—a doctor who specializes in preserving fertility for patients facing harsh chemotherapy [18][23]. They can evaluate baseline reproductive health and walk you through the most viable preservation options [24].
- Consult a financial navigator: Fertility preservation can be incredibly expensive. Because state insurance laws often specifically protect cancer patients, families of beta-thalassemia patients sometimes face frustrating coverage denials. A hospital social worker or financial counselor can help navigate these barriers.
- Remember there are multiple paths to family: Even if biological fertility preservation is not possible or successful, there are other ways to build a family in the future, including the use of donor eggs, donor sperm, or adoption.
Common questions in this guide
Why do beta-thalassemia gene therapies and stem cell transplants cause infertility?
Can children preserve their fertility before a stem cell transplant?
Does preserving my fertility mean I won't need hormone therapy?
How does iron overload affect fertility in beta-thalassemia?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific chemotherapy drugs will be used for the conditioning regimen, and what is their known impact on fertility and natural hormone production?
- 2.Can you refer us to an oncofertility specialist or reproductive endocrinologist immediately?
- 3.How much time will the fertility preservation process take, and how will it affect the timeline for starting the transplant or gene therapy?
- 4.What fertility preservation options are available at this hospital for someone of this age and pubertal stage?
- 5.Who can we speak with to understand the costs, annual storage fees, and insurance coverage options for these procedures?
- 6.Have the baseline fertility and reproductive hormone levels been checked, particularly considering any history of iron overload?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (24)
- 1
New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning.
Poinsignon V, Faivre L, Nguyen L, et al.
Pediatric blood & cancer 2020; (67(10)):e28603 doi:10.1002/pbc.28603.
PMID: 32706505 - 2
Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation.
Leonard A, Bertaina A, Bonfim C, et al.
Cytotherapy 2022; (24(3)):249-261 doi:10.1016/j.jcyt.2021.09.003.
PMID: 34879990 - 3
Male and Female Fertility: Prevention and Monitoring Hodgkin' Lymphoma and Diffuse Large B-Cell Lymphoma Adult Survivors. A Systematic Review by the Fondazione Italiana Linfomi.
Viviani S, Caccavari V, Gerardi C, et al.
Cancers 2021; (13(12)) doi:10.3390/cancers13122881.
PMID: 34207634 - 4
Testicular Tissue Banking for Fertility Preservation in Young Boys: Which Patients Should Be Included?
Delgouffe E, Braye A, Goossens E
Frontiers in endocrinology 2022; (13()):854186 doi:10.3389/fendo.2022.854186.
PMID: 35360062 - 5
Selecting β-thalassemia Patients for Gene Therapy: A Decision-making Algorithm.
Baronciani D, Casale M, De Franceschi L, et al.
HemaSphere 2021; (5(5)):e555 doi:10.1097/HS9.0000000000000555.
PMID: 33969274 - 6
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.
Locatelli F, Lang P, Wall D, et al.
The New England journal of medicine 2024; (390(18)):1663-1676 doi:10.1056/NEJMoa2309673.
PMID: 38657265 - 7
Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
Lüftinger R, Zubarovskaya N, Galimard JE, et al.
Annals of hematology 2022; (101(3)):655-665 doi:10.1007/s00277-021-04732-4.
PMID: 34999929 - 8
A mouse model of busulfan-induced ovarian toxicity and evidence for attenuation with mTOR inhibition.
Deguchi M, Tanaka Y, Nakamura A, et al.
Reproductive toxicology (Elmsford, N.Y.) 2026; (140()):109153 doi:10.1016/j.reprotox.2025.109153.
PMID: 41461242 - 9
Hematologic Conditions: Common Hemoglobinopathies.
Keber B, Lam L, Mumford J, Flanagan B
FP essentials 2019; (485()):24-31.
PMID: 31613565 - 10
Busulfan damages spermatogenic function by inducing orchitis.
Zhao L, Wu K, Xu S, et al.
PloS one 2025; (20(7)):e0322721 doi:10.1371/journal.pone.0322721.
PMID: 40694571 - 11
Late endocrine effects after hematopoietic stem cell transplantation in children with nonmalignant diseases.
de Kloet LC, Bense JE, van der Stoep MYEC, et al.
Bone marrow transplantation 2022; (57(10)):1564-1572 doi:10.1038/s41409-022-01755-x.
PMID: 35840745 - 12
Busulfan-Based and Treosulfan-Based Myeloablative Conditioning for Allogeneic Transplantation in Children with Thalassemia Major: a Single-Center Experience From Southern Turkey.
Aygüneş U, Karagun BS, Ay Tuncel D, et al.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2023; (21(11)):883-892 doi:10.6002/ect.2023.0143.
PMID: 38140932 - 13
New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement.
Carsote M, Vasiliu C, Trandafir AI, et al.
Diagnostics (Basel, Switzerland) 2022; (12(8)) doi:10.3390/diagnostics12081921.
PMID: 36010271 - 14
Pubertal Development and its Determinants in Adolescents With Transfusion-Dependent Thalassemia.
Singh P, Samaddar S, Parakh N, et al.
Indian pediatrics 2021; (58(7)):635-638.
PMID: 33772533 - 15
The effect of zinc deficiency and iron overload on endocrine and exocrine pancreatic function in children with transfusion-dependent thalassemia: a cross-sectional study.
Mousa SO, Abd Alsamia EM, Moness HM, Mohamed OG
BMC pediatrics 2021; (21(1)):468 doi:10.1186/s12887-021-02940-5.
PMID: 34686155 - 16
Complications in patients with transfusion dependent thalassemia: A descriptive cross-sectional study.
Faranoush M, Faranoush P, Heydari I, et al.
Health science reports 2023; (6(10)):e1624 doi:10.1002/hsr2.1624.
PMID: 37841947 - 17
Endocrine complications in patients with β-thalassemia major receiving iron-chelation therapy.
Al-Sanabra OM, Abbas MA, Hazàa AA, Hazà WJ
Therapeutic advances in endocrinology and metabolism 2025; (16()):20420188251406554 doi:10.1177/20420188251406554.
PMID: 41425691 - 18
Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignancies.
Poirot C, Fortin A, Dhédin N, et al.
Haematologica 2019; (104(8)):e360-e363 doi:10.3324/haematol.2018.211094.
PMID: 30765476 - 19
Pediatric oncofertility: an update.
Lau GA, Schaeffer AJ
Translational andrology and urology 2020; (9(5)):2416-2421 doi:10.21037/tau-20-991.
PMID: 33209715 - 20
ESHRE good practice recommendations on fertility preservation involving testicular tissue cryopreservation in children receiving gonadotoxic therapies†.
, Mitchell RT, Eguizabal C, et al.
Human reproduction (Oxford, England) 2025; (40(8)):1391-1431 doi:10.1093/humrep/deaf106.
PMID: 40574354 - 21
Impact of cancer and cancer treatment on male fertility.
Vakalopoulos I, Dimou P, Anagnostou I, Zeginiadou T
Hormones (Athens, Greece) 2015; (14(4)):579-89 doi:10.14310/horm.2002.1620.
PMID: 26732148 - 22
Fertility preservation in men: a contemporary overview and a look toward emerging technologies.
Brannigan RE, Fantus RJ, Halpern JA
Fertility and sterility 2021; (115(5)):1126-1139 doi:10.1016/j.fertnstert.2021.03.026.
PMID: 33933174 - 23
How Do Young Women with Cancer Experience Oncofertility Counselling during Cancer Treatment? A Qualitative, Single Centre Study at a Danish Tertiary Hospital.
Bentsen L, Pappot H, Hjerming M, et al.
Cancers 2021; (13(6)) doi:10.3390/cancers13061355.
PMID: 33802795 - 24
A predictive model for chemotherapy-related diminished ovarian reserve in reproductive-age women.
Hopeman MM, Cameron KE, Prewitt M, et al.
Fertility and sterility 2021; (115(2)):431-437 doi:10.1016/j.fertnstert.2020.08.003.
PMID: 33455812
This page discusses fertility risks associated with beta-thalassemia treatments for educational purposes only. Always consult your hematologist and a reproductive endocrinologist regarding your specific fertility preservation options.
Get notified when new evidence is published on Beta-thalassemia major.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.